171 related articles for article (PubMed ID: 32966884)
1. A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma.
Chen C; Lan MS
Cell Signal; 2020 Dec; 76():109785. PubMed ID: 32966884
[TBL] [Abstract][Full Text] [Related]
2. Repurposing a plant alkaloid homoharringtonine targets insulinoma associated-1 in N-Myc-activated neuroblastoma.
Chen C; Wu J; Hicks C; Lan MS
Cell Signal; 2023 Sep; 109():110753. PubMed ID: 37301315
[TBL] [Abstract][Full Text] [Related]
3. 5'-Iodotubercidin represses
Chen C; Breslin MB; Guidry JJ; Lan MS
J Biol Chem; 2019 Apr; 294(14):5456-5465. PubMed ID: 30755485
[TBL] [Abstract][Full Text] [Related]
4. Interplay: The Essential Role between INSM1 and N-Myc in Aggressive Neuroblastoma.
Chen C; Lan MS
Biology (Basel); 2022 Sep; 11(10):. PubMed ID: 36290282
[TBL] [Abstract][Full Text] [Related]
5. Small Molecules Targeting INSM1 for the Treatment of High-Risk Neuroblastoma.
Lan MS; Chen C
Biology (Basel); 2023 Aug; 12(8):. PubMed ID: 37627018
[TBL] [Abstract][Full Text] [Related]
6. INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma.
Chen C; Breslin MB; Lan MS
Oncotarget; 2015 Nov; 6(34):36700-12. PubMed ID: 26456864
[TBL] [Abstract][Full Text] [Related]
7. Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics.
Chen C; Notkins AL; Lan MS
Mol Cancer Res; 2019 Aug; 17(8):1597-1604. PubMed ID: 31113827
[TBL] [Abstract][Full Text] [Related]
8. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.
Gheeya JS; Chen QR; Benjamin CD; Cheuk AT; Tsang P; Chung JY; Metaferia BB; Badgett TC; Johansson P; Wei JS; Hewitt SM; Khan J
Cancer Biol Ther; 2009 Dec; 8(24):2386-95. PubMed ID: 19946221
[TBL] [Abstract][Full Text] [Related]
9. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
[TBL] [Abstract][Full Text] [Related]
10. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
11. Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.
Chen C; Breslin MB; Lan MS
Cell Signal; 2018 Jun; 46():83-91. PubMed ID: 29501727
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific promoter-driven adenoviral therapy for insulinoma.
Tseng AW; Chen C; Breslin MB; Lan MS
Cell Oncol (Dordr); 2016 Jun; 39(3):279-86. PubMed ID: 26902080
[TBL] [Abstract][Full Text] [Related]
13. INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.
Wang HW; Breslin MB; Chen C; Akerstrom V; Zhong Q; Lan MS
Hum Gene Ther; 2009 Nov; 20(11):1308-18. PubMed ID: 19604042
[TBL] [Abstract][Full Text] [Related]
14. FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
Wang J; Jiang J; Chen H; Wang L; Guo H; Yang L; Xiao D; Qing G; Liu H
Oncogene; 2019 Oct; 38(41):6737-6751. PubMed ID: 31406244
[TBL] [Abstract][Full Text] [Related]
15. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
[TBL] [Abstract][Full Text] [Related]
16. Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase.
Tseng AW; Akerstrom V; Chen C; Breslin MB; Lan MS
Int J Oncol; 2016 Jan; 48(1):173-80. PubMed ID: 26530405
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
18. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.
Lebedev T; Vagapova E; Spirin P; Rubtsov P; Astashkova O; Mikheeva A; Sorokin M; Vladimirova U; Suntsova M; Konovalov D; Roumiantsev A; Stocking C; Buzdin A; Prassolov V
Oncogene; 2021 Nov; 40(44):6258-6272. PubMed ID: 34556815
[TBL] [Abstract][Full Text] [Related]
19. Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Lang WH; Sandoval JA
J Biomol Screen; 2014 Oct; 19(9):1235-45. PubMed ID: 25092063
[TBL] [Abstract][Full Text] [Related]
20. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
